Investor Relations

BUILDING
THE Inevitable

Sheffield Laboratories is a private company. The information on this page is provided for existing investors and qualified prospective partners. It is not an offer to sell securities and should not be construed as financial advice, which frankly you should be getting from someone with a license.

Funding History

2019

$12M

Seed Round

Raised from four angel investors, one of whom Dr. Strauss describes as "the only person who understood what we were doing before we could explain it." Used to establish the Holmdel campus and hire the founding research team of 9.

2020

$85M

Series A

Led by Meridian Ventures with participation from Thematic Capital and one investor who requested anonymity "for professional reasons" and has maintained it successfully for five years. Funded the launch of the AI and ML research divisions.

2022

$310M

Series B

Oversubscribed by 4x. Closed in 11 days, which our CFO called "concerningly fast" and our CEO called "correctly fast." Expansion to Geneva and Singapore. Launch of the Moonshot Initiative (undisclosed at time of funding).

2023

$640M

Series C

Led by ARCH Longitude Partners. Valuation undisclosed at investor request but described by TechCrunch as "eye-watering" and by Dr. Strauss as "appropriate." First institutional backing from a sovereign wealth fund, identity undisclosed.

MAR 2025

$800M

Series D — Most Recent

Led by a sovereign wealth fund that has asked to remain anonymous "for reasons that will become clear." Valuation of $14B on a "pre-paradigm adjusted" basis — a term our CFO coined and our auditors have accepted under protest. Funds earmarked for Project ARISTOTLE commercial deployment, MERIDIAN enterprise expansion, and "infrastructure we cannot describe publicly."

Key Investors

Lead Investor — Series D

[Sovereign Wealth Fund]

Identity undisclosed at investor request. Board observer seat held under a pseudonymous holding entity. We are told they are "very happy." We take this on faith.

Institutional — Series B, C, D

ARCH Longitude Partners

Deep tech and frontier science focused fund with $18B AUM. Led our Series C. Dr. Strauss serves on their advisory board, which she notes "creates an interesting alignment dynamic."

Early Institutional — Series A

Meridian Ventures

Multi-stage technology fund. First institutional money into Sheffield. Managing partner David Chen has described the Sheffield investment as "the one that justifies everything else we've ever done." He says this at every LP meeting.

Strategic Partner

Thematic Capital

Thematic-investing fund with focus on science-forward technology. Participated in Series A through C. Has been consistently correct about Sheffield. Has been consistently wrong about the timeline.

Angel — Seed

The Four Angels

Four individuals who wrote checks in 2019 when there was nothing but a whiteboard and Dr. Strauss's certainty. Combined initial investment: $12M. Current paper value: not for this page. They know. They are pleased.

Strategic Interest — Undisclosed

[Redacted Entity]

Holds a small strategic stake acquired in conjunction with a research partnership we cannot describe. They have been good partners. That is genuinely all we can say.

Financial Overview

Sheffield Laboratories is a private company and does not publish full financial statements. The summary figures provided here are made available to existing investors and qualified prospects under NDA.

We operate a hybrid revenue model: commercial IP licensing (currently our largest revenue stream), direct deployment contracts with enterprise clients, and government research grants in domains we typically do not publicize.

We are not yet profitable on a GAAP basis. We are profitable on what our CFO calls an "intentionality-adjusted" basis, which is a measure he developed and which our auditors continue to review. We expect GAAP profitability in FY2026.

IP Licensing Revenue

$84M

$147M

$240M

Enterprise Contracts

$31M

$78M

$165M

Government Grants

$22M

$29M

$38M

Other / Undisclosed

—

$14M

$31M

Total Revenue

$137M

$268M

$474M

R&D Expenditure

($310M)

($480M)

($640M)

EBITDA (GAAP)

($183M)

($228M)

($187M)

EBITDA (Intentionality-Adjusted)

$47M

$112M

$240M

* Intentionality-Adjusted EBITDA adds back R&D expenditure classified as "paradigm-building investment" per Sheffield accounting methodology. Under audit review by Deloitte. Three auditors have asked for clarification. Two have accepted the explanation.

Investor Documents

📊

FY2025 Annual Impact Report

Published Q1 2025 — 48 Pages

View Report →

📋

Series D Investor Presentation

NDA Required — 94 Slides

Request Access →

🔬

Technology & IP Overview

For Qualified Investors Only

Request Access →

📅

Q1 2025 Investor Update

Distributed to existing LPs

IMPORTANT NOTICE: The information contained on this page does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sheffield Laboratories, Inc. ("Sheffield" or the "Company"). Any such offering may only be made pursuant to a definitive private placement memorandum and is subject to the completion of due diligence, legal review, and the execution of definitive agreements. Forward-looking statements on this page, including revenue projections, valuation estimates, and references to "intentionality-adjusted" financial metrics, involve known and unknown risks and uncertainties. The term "pre-paradigm adjusted valuation" has not been endorsed by the SEC, FASB, or any other regulatory body. Sheffield makes no representation that it will be. Past paradigm shifts are not necessarily indicative of future paradigm shifts.

BUILDINGTHE Inevitable

BUILDING
THE Inevitable